Stammdaten
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | MetaVia Inc. |
|---|---|
| Ticker | MTVA |
| CIK | 0001638287 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,5 Mio. USD |
| Beta | 0,35 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -12,973,000 | -7.35 | 11,123,000 | 5,333,000 | |
| 2025-09-30 | 10-Q | -3,377,000 | -0.14 | 14,765,000 | 6,331,000 | |
| 2025-06-30 | 10-Q | -3,995,000 | -0.26 | 18,459,000 | 9,624,000 | |
| 2025-03-31 | 10-Q | -3,671,000 | -0.36 | 12,127,000 | 4,380,000 | |
| 2024-12-31 | 10-K | -27,592,000 | -39.13 | 16,260,000 | 7,931,000 | |
| 2024-09-30 | 10-Q | -5,652,000 | -0.55 | 22,146,000 | 12,953,000 | |
| 2024-06-30 | 10-Q | -10,053,000 | -1.85 | 28,751,000 | 18,942,000 | |
| 2024-03-31 | 10-Q | -6,714,000 | -1.32 | 17,018,000 | 10,076,000 | |
| 2023-12-31 | 10-K | -12,470,000 | -2.46 | 22,781,000 | 16,685,000 | |
| 2023-09-30 | 10-Q | -3,818,000 | -0.75 | 26,425,000 | 21,550,000 | |
| 2023-06-30 | 10-Q | -734,000 | -0.15 | 29,179,000 | 25,196,000 | |
| 2023-03-31 | 10-Q | -2,604,000 | -0.51 | 31,488,000 | 20,508,000 | |
| 2022-12-31 | 10-K | -13,967,000 | -43.42 | 33,534,000 | 21,750,000 | |
| 2022-09-30 | 10-Q | -3,113,000 | -3.50 | 7,557,000 | 5,938,000 | |
| 2022-06-30 | 10-Q | -3,303,000 | -3.72 | 10,082,000 | 8,833,000 | |
| 2022-03-31 | 10-Q | -2,875,000 | -3.24 | 13,461,000 | 11,928,000 | |
| 2021-12-31 | 10-K | -15,284,000 | -19.81 | 16,799,000 | 14,597,000 | |
| 2021-09-30 | 10-Q | -3,461,000 | -4.66 | 8,077,000 | 6,125,000 | |
| 2021-06-30 | 10-Q | -3,921,000 | -0.18 | 10,719,000 | 9,478,000 | |
| 2021-03-31 | 10-Q | -3,324,000 | -0.15 | 14,160,000 | 13,151,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.